<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306837</url>
  </required_header>
  <id_info>
    <org_study_id>Lym-Auto-RJH-2014</org_study_id>
    <nct_id>NCT02306837</nct_id>
  </id_info>
  <brief_title>Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies</brief_title>
  <official_title>A Phase II Trial of Consolidation Chemothetapy for Patients With Relapse or Refractory Lymphoid Malignancies After Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical
      trial to test the efficacy and feasibility of consolidation chemotherapy after autologous
      stem cell transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with relapsed or refractory lymphoma will be included. All patients will undergo
      PBSC mobilization with CTX and G-CSF. After sucessful collection of CD34+ over 1x109/L,
      autologous stem cel ltransplantation with Bu-Cy-E conditioning will be given. Two months
      after auto-HSCT, a PET-CT will be performed and all patients with CR, CRu and PR will
      recieved 3 cycles of mini-Bu-Cy-E as consolidation 3, 6 and 9 months after auto-HSCT. For
      patients with SD or PD after auto-HSCT will refered to the allogeneic transplantatio program
      and take off the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression</measure>
    <time_frame>2-year</time_frame>
    <description>PET-CT measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplantation-related mortality</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Consolidation chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bu-CY-E</intervention_name>
    <description>mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT</description>
    <arm_group_label>Consolidation chemo</arm_group_label>
    <other_name>mini Bu-Cy-E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed or refracotry NHL or HD: PR or SD after first line salvage
             chemotherapy;

          -  ECOG: 0-2

          -  Tbil &lt; 1.5x ULN and AST/ALT &lt;2.5x ULN

          -  With informed consent

        Exclusion Criteria:

          -  Life expectancy &lt; 3 months

          -  Women in pregnancy

          -  uncontrollable infection disease

          -  serum Cr &gt;400mmol/l

          -  uncontroled diabetis and heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Hu, M.D,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai Jiaotong Unic\versity School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong Hu, M.D,</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.</last_name>
      <phone>0086-64370045</phone>
      <phone_ext>601818</phone_ext>
      <email>hujiong@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jiong HU, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai No 10 Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JunMei Shi, M.D, Ph.D,</last_name>
    </contact>
    <investigator>
      <last_name>JunMei Shi, M.D, Ph.D,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood &amp; Marrow Transplantation Center</investigator_title>
  </responsible_party>
  <keyword>lymphoma, consolidation chemotherapy, auto-HSCT</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

